CCC-003 suppresses tumor growth in human ALK-mutated neuroblastoma xenograft models.
(A, B, C) SH-SY5Y cells were subcutaneously injected into the flanks of female immune-deficient BALB/c nu/nu mice. Administration of CCC-003 began when the average tumor size reached 500 mm3. (A) The tumor volume of mice was measured twice a week. Red arrows indicate the timepoints of CCC-003 administration. P-values were determined using repeated measures ANOVA followed by a Bonferroni post-hoc test (*, P < 0.05). Data are presented as the mean ± SD. DMSO was used as a control. (B) Representative images of mice with SH-SY5Y xenografts at 24 h after administration. (C) Representative images of SH-SY5Y xenograft tumors at 24 h after administration. At 24 h after administration, the tumor tissues were collected and used for immunohistochemistry with HE and an anti-cleaved caspase-3 antibody. Scale bars, 50 μm. (D) The number of cleaved caspase-3-positive cells was determined in tumor tissues. P-values were determined using a paired t-test (***, P < 0.001).